METTL3 and chronic myelogenous leukemia, BCR-ABL1 positive: Silencing METTL3 in K562 cells and the TKI imatinib mesylate-resistant K562 cell line (K562r), they found that METTL3 affects the growth and viability of CML cells directly and indirectly.